IRMD
HealthcareIRadimed Corporation · Medical - Devices · $1B
What is IRadimed Corporation?
IRadimed Corporation specializes in MRI-compatible medical devices — a narrow but critical niche within the healthcare equipment market. Headquartered in Winter Springs, Florida, the company serves hospitals and imaging centers across the United States and internationally.
IRadimed designs and manufactures devices that can safely operate inside MRI environments, where conventional electronics are incompatible with powerful magnetic fields. Its primary revenue comes from selling MRI-compatible IV infusion pumps and patient vital signs monitoring systems, along with related disposables and accessories. Products are sold through a direct sales force and independent distributors to hospitals, acute care facilities, and outpatient imaging centers.
IRadimed was incorporated in 1992 and is headquartered in Winter Springs, Florida.
- MRidium MRI-compatible IV infusion pump system
- MRI-compatible patient vital signs monitoring system
- Disposable IV tubing sets and SpO2 monitoring accessories
- Non-magnetic IV poles, wireless remote displays, and dose error reduction systems
Is IRMD a Good Stock to Buy?
UQS Score rates IRMD as Good overall, reflecting a balanced profile with notable strengths and one area of caution.
The Quality and Risk pillars both score Strong, suggesting the business generates reliable financial results while maintaining a conservative balance sheet and operational profile. The Growth pillar also registers as Good, indicating the company is expanding at a pace that compares favorably within its peer group.
The Valuation pillar is rated Elevated, meaning the market may already be pricing in a significant portion of IRadimed's future prospects — a consideration for cost-conscious investors.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does IRMD pay dividends?
Yes — IRadimed Corporation pays a dividend.
IRadimed pays a regular dividend, which is relatively uncommon among small-cap medical device companies. This reflects management's confidence in the durability of its cash generation. Income-oriented investors may find the dividend meaningful, though the Elevated Valuation pillar is worth weighing alongside the yield.
When does IRMD report earnings?
IRadimed reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Strong Quality and Risk pillar ratings suggest earnings have been relatively consistent, without the volatility common in early-stage medical device peers. Revenue growth appears steady, supported by recurring disposables and service revenue alongside capital equipment sales.
For the most recent quarter's results, visit IRadimed Corporation's investor relations page directly.
IRMD Price History
+251.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in IRadimed Corporation?
Based on IRadimed Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
IRMD Long-term Outlook
IRadimed's Good Growth pillar points to a business with meaningful expansion potential, likely driven by increasing MRI procedure volumes and growing adoption of MRI-safe equipment standards in hospitals. The Strong Risk pillar suggests the company is well-positioned to navigate near-term uncertainty. However, the Elevated Valuation pillar indicates that much of this optimism may already be reflected in the current share price.
Growth drivers
- Rising global demand for MRI procedures and MRI-safe clinical workflows
- Expansion into international markets through distributor partnerships
- Recurring revenue from disposable IV tubing sets and service contracts
Key risks
- Elevated valuation leaves limited margin of safety if growth disappoints
- Narrow product focus creates concentration risk if MRI-compatible device standards shift
- Small-cap scale may limit pricing power against larger hospital procurement systems
IRMD vs Peers
IRadimed competes in the broader medical device space, though its MRI-specific focus sets it apart from more diversified peers.
CONMED offers a broad surgical device portfolio across multiple specialties, contrasting with IRadimed's concentrated focus on MRI-compatible equipment.
Avanos targets pain management and respiratory care markets, giving it a different clinical footprint than IRadimed's imaging-suite niche.
Butterfly Network focuses on portable ultrasound technology, competing in medical imaging but through a fundamentally different modality than MRI.
Frequently Asked Questions
What does IRadimed Corporation do?
IRadimed develops and manufactures medical devices specifically engineered to function safely inside MRI environments. Its core products include an MRI-compatible IV infusion pump and a patient vital signs monitoring system, along with related disposables and accessories. The company sells to hospitals, acute care facilities, and outpatient imaging centers in the US and internationally.
Does IRMD pay dividends?
Yes, IRadimed pays a regular dividend — an uncommon trait for a small-cap medical device company. This signals management's confidence in the company's ability to generate consistent cash. Investors should review the current dividend details on IRadimed's investor relations page, as amounts and timing can change.
When does IRMD report earnings?
IRadimed reports earnings quarterly, in line with standard US-listed company practice. For the exact schedule and most recent results, check the investor relations section of IRadimed's official website.
Is IRMD a good stock to buy?
UQS Score rates IRMD as Good overall, with Strong marks in Quality and Risk and a Good Growth rating. The main caution is an Elevated Valuation pillar, which suggests the stock may not offer a wide margin of safety at current prices. Pro members can view the complete pillar breakdown to form their own assessment.
Is IRMD overvalued?
The UQS Valuation pillar for IRMD is rated Elevated, meaning the stock appears priced above what might be considered conservative fair value relative to its fundamentals. This does not necessarily mean the stock will decline, but it does suggest investors are paying a premium for IRadimed's quality and growth profile.
How does IRMD compare to its competitors?
IRadimed occupies a specialized niche — MRI-compatible devices — that distinguishes it from broader medical device peers like CONMED and Avanos Medical. Unlike Butterfly Network, which targets ultrasound imaging, IRadimed's entire product line is built around the unique constraints of the MRI environment, giving it a focused but narrow competitive position.
What is IRMD's market cap bracket?
IRMD is classified as a small-cap stock. This means it carries the growth potential often associated with smaller companies but may also experience greater price volatility and lower trading liquidity compared to large- or mega-cap healthcare names.
Who founded IRadimed Corporation?
IRadimed was incorporated in 1992. Founding details are widely available through the company's public filings and official corporate history on its investor relations page.
Is IRMD a long-term quality investment?
From a quality indicator standpoint, IRMD's Strong Quality and Risk pillar ratings suggest the business has durable fundamentals. Long-term investors should weigh this against the Elevated Valuation pillar, which may affect entry-point attractiveness. The full UQS analysis, available to Pro members, provides a deeper view of sustainability across all five pillars.
What is the main competitive advantage of IRadimed Corporation?
IRadimed's primary advantage is its specialization in MRI-compatible technology — a technically demanding area with high regulatory barriers and limited direct competition. Hospitals seeking to safely administer IV therapy or monitor patients inside an MRI scanner have few qualified alternatives, which supports IRadimed's market position.
Unlock Full IRMD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings for IRMD
- ✓Access detailed financial metrics and trend data
- ✓Compare IRMD side-by-side with competitors on quality and valuation
- ✓See the complete risk breakdown behind the Strong Risk pillar rating
- ✓Get the full analyst-style view available exclusively to Pro members
Pro Analysis
IRMD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 60.7 | 84.9 | 41.0 | 63.6 | 82.4 | 27.7 | -0.2 |
| May 19, 2026 | 60.9 | 85.0 | 41.0 | 63.6 | 82.4 | 28.9 | -0.2 |
| May 16, 2026 | 61.1 | 85.1 | 41.0 | 63.6 | 82.4 | 30.1 | +0.3 |
| May 7, 2026 | 60.8 | 82.8 | 41.0 | 65.7 | 82.4 | 28.9 | +0.1 |
| May 3, 2026 | 60.7 | 82.8 | 41.0 | 65.7 | 82.4 | 28.4 | +0.1 |
| Apr 26, 2026 | 60.6 | 82.8 | 41.0 | 65.7 | 82.4 | 27.6 | +0.4 |
| Apr 19, 2026 | 60.2 | 82.8 | 41.0 | 65.7 | 82.4 | 24.7 | -0.1 |
| Apr 18, 2026 | 60.3 | 82.8 | 41.0 | 65.7 | 82.4 | 25.6 | -0.9 |
| Apr 17, 2026 | 61.2 | 82.8 | 41.0 | 65.7 | 82.4 | 32.0 | +0.1 |
| Apr 16, 2026 | 61.1 | 82.8 | 41.0 | 65.7 | 82.4 | 30.9 | -0.2 |
IRMD — Pillar Breakdown
Quality
— 84.8/100 (25%)IRadimed Corporation demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 63.6/100 (20%)IRadimed Corporation demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)IRadimed Corporation carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 26.9/100 (15%)IRadimed Corporation appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 41/100 (25%)IRadimed Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for IRMD.
Score Composition
Financial Data
More Stock Analysis
How is the IRMD UQS Score Calculated?
The UQS (Unified Quality Score) for IRadimed Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses IRadimed Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether IRadimed Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.